Category: School — Medicine

Harnessing this process may offer therapies for neuroinflammatory diseases such as MS, mouse study suggests

Recognized for innovative research with potential clinical impact

The Needleman Program for Innovation and Commercialization provides funding for researchers developing promising new therapeutics, helping them progress to early-stage clinical trials. A second call for proposals is now open. The submission deadline is March 15. Learn more here (WUSTL Box login required). 

Washington University and Deerfield Management announced the launch of VeritaScience, a new private R&D collaboration designed to advance the discovery, clinical development and commercialization of promising therapeutic and diagnostic candidates with potential to benefit human health.

Understanding the brain and nervous system is one of the most pressing challenges in medicine. To meet this challenge, WashU Medicine has built and is opening the Neuroscience Research Building, a 609,000-square-foot facility expected to be among the nation’s premier neuroscience research hubs.

David T. Curiel, MD, PhD, and James W. Janetka, PhD – both of Washington University School of Medicine in St. Louis – have been named fellows of the National Academy of Inventors (NAI). The recognition represents the highest professional distinction accorded solely to academic inventors.

Shripad Bhagwat, PhD, a drug development expert with decades of experience in the pharmaceutical and biotech industries, has been named the inaugural senior director of the Needleman Program for Innovation and Commercialization (NPIC) at Washington University in St. Louis. 

Membership is one of highest U.S. honors in health and medicine

One of 3 researchers honored for their research on how microbiomes function

Sonobiopsies generate genetic, molecular data to inform treatment decisions for brain diseases

Scientists at Washington University in St. Louis have developed a breath test that quickly identifies those who are infected with the virus that causes COVID-19. The device requires only one or two breaths and provides results in less than a minute.

Gut microbiome pioneer receives one of highest honors in Spanish-speaking world

Scientists, engineers receive small-business development grant

Researchers ID shortcomings in stem cell-derived beta cells, paving way to improved diabetes treatments

Award will help advance neuroscience technologies aimed at improving cognitive wellness

Up to $4 million in funding available to pursue ‘investigational new drug’ status

Washington University School of Medicine in St. Louis scientists Michael S. Diamond, MD, PhD, and Sean Whelan, PhD, lead a team working to minimize the risk of another devastating coronavirus pandemic by designing a vaccine that reduces sickness and death caused by all potentially deadly coronaviruses, including ones that have not yet affected people. The research is supported by an $8 million grant from the National Institute for Allergy and Infectious Diseases of the National Institutes of Health (NIH).

Noninvasive technique could shed light on preterm birth

Research flourishes despite the immense challenges of the pandemic

‘Father of the field’ honored for gut microbiome research

The world’s first nasal vaccine for COVID-19 was approved Tuesday, Sept. 6, in India for emergency use. The vaccine, called iNCOVACC, is based on technology licensed from Washington University in St. Louis and developed in collaboration with Bharat Biotech International Limited in India.